The Latest Breaking News from GPCR

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

MarketBeat · Apr 17

3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

MarketBeat · Mar 16

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga · Aug 7, 2025

This Weight-Loss Stock Could Surge 75%, Says JPMorgan

Structure Therapeutics is a clinical-stage weight-loss company that is poised to gain traction in a rapidly expanding addressable market.

Barchart · May 29, 2024

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Barchart · Apr 18, 2024